 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...1718192021222324252627...235236» |
- Fruzaqla (fruquintinib) / Takeda
Comparative analysis of first-line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort study compared with propensity score matching (PSM) cohort. (Hall A; Poster Bd #: 254) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2660;
P2
Similar to the primary analysis, the safety profile was generally manageable with longer duration of treatment exposure. Fruquintinib combined with mFOLFOX6/FOLFIRI might be a more promising treatment option as first-line therapy for mCRC pts.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study). (Hall A; Poster Bd #: 253) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2659;
Fruquintinib combined with mFOLFOX6/FOLFIRI might be a more promising treatment option as first-line therapy for mCRC pts. These preliminary data suggest that CGP of mCRC patients can identify prognostic genomic signatures, which might allow a better stratification of patients and the identification of subgroups that might benefit a treatment de-escalation strategy.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Time to target TIM-3 in colorectal cancer: TIM-3 expression to predict survival outcomes in patients in CALGB (Alliance)/SWOG 80405. (Hall A; Poster Bd #: 246) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2652;
P3
CRC KRAS WT tumors with liver metastases have worse prognosis with high TIM3 exp. TIM3 exp is also predictive of survival in pts treated with FOLFOX and Cet-based treatment.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Neoadjuvant chemotherapy with atezolizumab, bevacizumab, and FOLFOX for patients with unresectable colorectal liver metastases: A translational pilot study. (Hall A; Poster Bd #: 236) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2642;
Neoadjuvant ABFOLFOX induced durable responses more than 24 months with or without LTM in 37% of pts with unresectable CRLM. Serial immune cell expansion was identified in CRLM of good responders, suggesting immune monitoring can be useful in identifying pts who may derive durable benefits from ICIs in CRLM.
- 5-fluorouracil / Generic mfg.
Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial. (Hall A; Poster Bd #: 235) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2641;
Serial immune cell expansion was identified in CRLM of good responders, suggesting immune monitoring can be useful in identifying pts who may derive durable benefits from ICIs in CRLM. TRIPLETE is a phase III trial where 435 pts with untreated RAS/BRAF wt
- oxaliplatin / Generic mfg.
New drugs to prevent oxaliplatin-induced peripheral neuropathy: A double-blind, randomized study. (Hall A; Poster Bd #: 231) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2637;
Notably, the study group also had a significantly greater number of cycles before HSR. These results show that PC-SOD may suppress HSR as well as PN, both of which limit administration of oxaliplatin.
- irinotecan / Generic mfg.
Effect of p16 immunohistochemical expression (exp) on irinotecan in metastatic colorectal cancer (mCRC): A translational analysis of the TRIBE and TRIBE2 studies. (Hall A; Poster Bd #: 225) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2631;
In mCRC, p16 pos exp seems associated with higher benefit from irinotecan. Prospective confirmation in independent randomized series is warranted.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study. (Hall A; Poster Bd #: 222) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2628;
P2
Treatment with a combination of encorafenib and cetuximab is effective and well tolerated in Chinese patients with BRAF V600E mutant mCRC, resulting in a significantly longer PFS than standard therapies. These results are consistent with those previously reported in the BEACON study.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Efficacy of FOLFIRI plus bevacizumab versus FOLFIRI plus cetuximab in RAS-mutant metastatic colorectal cancer: Final update on patients with RAS-mutant metastatic colorectal cancer treated in FIRE-3. (Hall A; Poster Bd #: 213) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2619;
P3
While cetuximab notably is not effective in RASmut mCRC, this randomized comparison does not provide an indication for superior efficacy of bevacizumab in the first-line treatment of this patient group. Trial identification number: NCT00433927 [clinicaltrials.gov]
- Vectibix (panitumumab) / Amgen
Spatial patterns in the tumor immune microenvironment as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab+FOLFOX induction in RAS wildtype (wt) metastatic colorectal cancer (mCRC): PanaMa (AIO KRK0212) trial. (Hall A; Poster Bd #: 202) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2609;
Several factors of the immune microenvironment were found to be prognostic factors for PFS and OS in patients with RAS wt mCRC. Of those, CD8, CD163, LAG3, CD45, Immunoscore, and an Immunoactivation-score were identified as independent predictive markers for benefit from the addition of Pmab to FU/FA maintenance therapy, suggesting that immune activation might be a crucial component of EGFR-antibody efficacy.
- 5-fluorouracil / Generic mfg.
Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial. (Hall A; Poster Bd #: 200) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2607;
P3
To the best of our knowledge, this is the first randomized controlled trial investigating the time required for adjuvant chemotherapy for colon cancer. The findings reveled that adjuvant chemotherapy within 2 weeks after surgery for stage III colon cancer did not prolong disease-free survival.
- Vectibix (panitumumab) / Amgen
AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab (pan) plus 5 fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer (Hall A; Poster Bd #: 198) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2605;
6-month PFS in both arms was consistent with the hypothesized rate of 73% achieved with FU/bev, whilst the rate was numerically higher for arm B. Baseline comprehensive geriatric assessments were feasible and OTU was high in both arms. Both treatment arms might be suitable first-line options in appropriately selected patients.
- Avastin (bevacizumab) / Roche
A phase II clinical trial of metformin combined with FOLFIRI plus bevacizumab as second-line therapy in patients with RAS-mutant metastatic colorectal cancer. (Hall A; Poster Bd #: 197) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2604;
This single-arm, multicenter trial (ChiCTR2000037943) recruited patients with RAS mutant mCRC that had failed to first-line bevacizumab plus an oxaliplatin-based regimen of systemic therapies. Patients received metformin 1000mg PO twice daily on day 1-14, plus irinotecan 180 mg/m
- Neoadjuvant chemotherapy with FOLFOXIRI plus lateral lymph nodes dissection for the treatment of resectable rectal cancer with lateral lymph node metastasis: A single-arm, investigator-initiated, phase II trial. (Hall A; Poster Bd #: 196) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2603;
P=N/A
We conducted the present phase II trial by performing neoadjuvant chemotherapy with 5-fluorouracil, irinotecan, and oxaliplatin (FOLFOXIRI) regimen plus lateral lymph node dissection (LLND) for resectable rectal cancer with LLNM to decrease the lateral recurrence and distant metastasis rates...Total mesorectal excision plus LLND was performed at 3-4 weeks after completing the last cycle of preoperative chemotherapy, followed by 3 cycles of XELOX... Neoadjuvant chemotherapy with the FOLFOXIRI regimen plus LLND can significantly reduce the risk of local recurrence and distant metastasis in resectable rectal cancer with LLNM, which may be a new treatment option.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa. (Hall A; Poster Bd #: 192) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2599;
CMS were confirmed as prognostic biomarkers and might contain predictive information for the choice of anti-EGFR or anti-VEGF antibodies in RAS WT mCRC. Prospective validation remains mandatory.
- Vectibix (panitumumab) / Amgen
Combined amphiregulin and epiregulin expression as a prognostic and predictive biomarker of panitumumab (Pmab), fluorouracil, and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab+FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212). (Hall A; Poster Bd #: 191) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2598;
Combined AREG and EREG mRNA expression was confirmed as prognostic biomarker for mCRC patients receiving maintenance treatment. Efficacy of maintenance treatment might potentially be higher for Pmab+FUFA maintenance in mCRC with high combined AREG / EREG expression in the PanaMa trial.
- Highly prognostic signature for stage II colon cancer from the TOSCA trial: The PROSIT study. (Hall A; Poster Bd #: 187) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2594;
Fifty-seven percent of the patients received FOLFOX, while the remaining were treated with XELOX... The new transcriptomic signature may help in identifying stage II CC patients who are likely to relapse despite receiving adjuvant oxaliplatin-based treatment.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Characterization of necroptosis activators in colorectal cancer. (Hall A; Poster Bd #: 185) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2592;
The new transcriptomic signature may help in identifying stage II CC patients who are likely to relapse despite receiving adjuvant oxaliplatin-based treatment. NA-H showed significantly improved OS in FOLFOX/FOLFIRI (F/F) (NA-L: 34.3 vs NA-H: 39.6 months [mo], P< 0.001; HR = 0.83, 95% CI 0.77
- DEP irinotecan (SN38-SPL9111) / Starpharma
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial. (S406) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2176;
P1/2
DEP SN38 shows promising clinical utility with encouraging antitumor activity including prolonged disease control & durable PRs in heavily pre-treated CRC, HGSOC & BC pts. DEP SN38 is well-tolerated with significantly fewer severe gastrointestinal TRAEs compared to c-IRI, & warrants further clinical assessment.
- CV6-168 / CV6 Therap
A modular, open-label, phase I/IIa study to evaluate the safety, tolerability, pharmacokinetics (PKs) and anti-tumour activity of a first-in-class (FIC) specific dUTPase inhibitor CV6-168 combined with anti-cancer treatments in patients (pts) with advanced malignancies. (Hall A; Poster Bd #: 310a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2141;
This trial design 1) Allows one protocol responsive to emerging data for a compound with multiple hypotheses, supporting studies in multiple combinations, reducing time from emerging data to 'first subject in study" compared with multiple individual studies; 2) Has the potential to reduce the number of pts unnecessarily exposed to a novel agent; and 3) Allows investigators to pre-empt emerging data and changes to the treatment landscape. These challenges in oncology drug development emphasize the need for flexible designs as the landscape of drug development continually evolves.
- AZD0901 / AstraZeneca
CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors. (Hall A; Poster Bd #: 306b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2134;
P1, P2
Secondary endpoints include overall survival, progression-free survival, duration of response, disease control rate, best change in target lesion size, pharmacokinetics, immunogenicity, and pharmacodynamics. Recruitment began in December 2023, and sites across Australia, Asia, Europe, and North America will enroll patients.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical and molecular characterization of AXL in colorectal cancer: CALGB (Alliance)/SWOG 80405 and real-world data. (Hall A; Poster Bd #: 290) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2116;
P3
AXL-H confers worse OS/PFS on first-line chemotherapy, with a more pronounced effect in KRASwt CRC. This data supports evaluation of AXL as a prognostic marker and potential therapeutic target in CRC.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Association of KRAS G12D vs. G12V circulating tumor DNA variant allele fraction and real-world overall survival in metastatic non-small cell lung and colorectal cancers. (Hall A; Poster Bd #: 186) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2016;
In contrast, for mCRC both G12D and G12V VAF were associated with rwOS, including for the subset of patients who received chemotherapy. These data suggest a complex interplay between KRAS variant, ctDNA shedding, first-line treatment, and OS that will be important in the interpretation of the prognostic implications of ctDNA-identified KRAS alterations.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
A multicenter phase II study of modified FOLFIRINOX for first-line treatment for advanced urachal cancer (ULTMA; KCSG GU20-03). (S100bc) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1677;
P2
The regimen is well tolerated without febrile neutropenia with prophylactic pegteograstim. Further analysis of efficacy will be presented.
- Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma. (Hall A; Poster Bd #: 303) - Apr 24, 2024 - Abstract #ASCO2024ASCO_829;
P2
Longer follow-up is required for the accurate assessment of OS. No significant toxicity increases were observed with the addition of UV1.
- | leucovorin calcium / Generic mfg.
Preclinical, Journal: Engineering 5-flourouracil and leucovorin-loaded vesicular systems for possible colon specific delivery: In vitro evaluation and real time cell assay against HCT-116 colon cell lines. (Pubmed Central) - Apr 24, 2024
No significant toxicity increases were observed with the addition of UV1. The sequential drug release of the colon-targeted capsules containing 5-FU and LEU- loaded proniosomes showed negligible drug release in SGF (pH 1.2) and phosphate buffer solution (pH 6.8) (approximately 11
- | Keytruda (pembrolizumab) / Merck (MSD), Visudyne (verteporfin) / Novartis
New P2 trial, Metastases: Photoradiation with Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 24, 2024
P2, N=25, Not yet recruiting, Sponsor: Mayo Clinic
- || Saltikva (attenuated Salmonella typhimurium expressing IL-2) / MD Biosciences, Salspera
Enrollment closed, Metastases: Saltikva for Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 24, 2024
P2, N=60, Active, not recruiting, Sponsor: Salspera LLC
The sequential drug release of the colon-targeted capsules containing 5-FU and LEU- loaded proniosomes showed negligible drug release in SGF (pH 1.2) and phosphate buffer solution (pH 6.8) (approximately 11 Recruiting --> Active, not recruiting
- ||||||| Vectibix (panitumumab) / Amgen
Trial completion, Real-world evidence: Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix (clinicaltrials.gov) - Apr 23, 2024
P=N/A, N=647, Completed, Sponsor: iOMEDICO AG
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| napabucasin (BBI608) / Sumitomo Pharma
New P3 trial, Combination therapy, Metastases: This study is to understand how well an investigational drug (called Napabucasin) works when given in combination with a chemotherapy treatment for people with colorectal cancer after all available standard treatments. (EUDRACT) - Apr 23, 2024
P3, N=668, Ongoing, Sponsor: 1Globe Health Institute
- Imfinzi (durvalumab) / AstraZeneca
PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB PLUS 5-FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND DOCETAXEL (FLOT) IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC): REGIONAL SUBGROUP ANALYSIS FROM THE PHASE 3 MATTERHORN STUDY (207B - Walter E. Washington Convention Center) - Apr 23, 2024 - Abstract #DDW2024DDW_8550;
- || sirexatamab (DKN-01) / Leap Therap
Trial completion date, Trial primary completion date, Metastases: DeFianCe: Phase 2 Study of DKN-01 in Colorectal Cancer (clinicaltrials.gov) - Apr 23, 2024
P2, N=150, Recruiting, Sponsor: Leap Therapeutics, Inc.
Active, not recruiting --> Completed Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Dec 2025
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Trial completion date, Surgery: acns0333: Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System (clinicaltrials.gov) - Apr 22, 2024
P3, N=70, Completed, Sponsor: Children's Oncology Group
Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Dec 2025 Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Mar 2024
- | Avastin (bevacizumab) / Roche
Journal, Metastases: The Safety and Effectiveness of Bevacizumab in Metastatic Colorectal Cancer With Unresectable Metastases: A Real-Life Study From the South of Morocco. (Pubmed Central) - Apr 22, 2024
Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Mar 2024 In the first line, all
- ||| AMG 193 / Amgen
Enrollment open: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Apr 22, 2024
P1, N=282, Recruiting, Sponsor: Amgen
In the first line, all Not yet recruiting --> Recruiting
- ||| Imfinzi (durvalumab) / AstraZeneca
Clinical guideline, Review, Journal, PD(L)-1 Biomarker, IO biomarker: Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT). (Pubmed Central) - Apr 22, 2024
These guidelines are intended to provide a personalised therapeutic strategy for daily clinical practice. Each individual BTC case should be discussed by a multidisciplinary team.
- || Avastin (bevacizumab) / Roche
Retrospective data, Review, Journal, Head-to-Head, Metastases: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. (Pubmed Central) - Apr 22, 2024
We evaluated the relative efficacy and safety of first-line EGFRIs plus doublet chemotherapy (FOLFIRI or FOLFOX) vs. bevacizumab plus doublet chemotherapy for patients with RAS WT left-sided mCRC, as well as in all- and right-sided tumors...Safety was available in 6 trials for all-sided tumors and 1 trial for left-sided tumors, each demonstrating typical class-specific adverse events. This most comprehensive meta-analysis indicates a benefit for first-line EGFRI plus chemotherapy over bevacizumab plus chemotherapy in patients with left-sided RAS WT mCRC.
- | Sulanda (surufatinib) / Hutchmed
New trial, Metastases: The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Apr 22, 2024
P=N/A, N=72, Completed, Sponsor: Luo Cong
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment open: Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (clinicaltrials.gov) - Apr 22, 2024
P3, N=408, Recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
This most comprehensive meta-analysis indicates a benefit for first-line EGFRI plus chemotherapy over bevacizumab plus chemotherapy in patients with left-sided RAS WT mCRC. Not yet recruiting --> Recruiting
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
GOBLET CELL ADENOCARCINOMA AND RESPONSE TO TREATMENT - SINGLE CENTER EXPERIENCE OF A RARE MALIGNANCY (Room 207B) - Apr 21, 2024 - Abstract #SSAT2024SSAT_406;
Patients with stage II disease have modest 5-year survival with surgical resection and selective use of adjuvant chemotherapy. Patients with peritoneal metastases can have long-term survival when treated with a combination of systemic chemotherapy, cytoreductive surgery, and HIPEC, though the role of the treatment itself versus careful patient selection remains unknown.
- 5-fluorouracil / Generic mfg.
CAN TUMOR RESPONSE TO INDUCTION CHEMOTHERAPY PREDICT TME-FREE SURVIVAL AFTER TOTAL NEOADJUVANT THERAPY FOR LOCALLY ADVANCED RECTAL CANCER? (Room 207A) - Apr 21, 2024 - Abstract #SSAT2024SSAT_333;
Our data indicate that when an organ preservation strategy is pursued, the tumor response to induction chemotherapy predicts the probability of TME-free survival early in the treatment course. This benefit of induction chemotherapy should be considered when the chemotherapy sequence or treatment escalation and de-escalation, based on tumor response, is investigated in future research designed to maximize organ preservation.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
TREATMENT OF RECTAL CANCER BY TOTAL NEOADJUVANT THERAPY AND TRANSANAL LIMITED LOCAL EXCISION FOR COMPLETE RESPONDERS: PHASE II TRIAL RESULTS (Room 207A) - Apr 21, 2024 - Abstract #SSAT2024SSAT_331;
All patients received 6 cycles of induction FOLFOX followed by concurrent Capecitabine/5FU infusion and external beam radiation...All patients completed total neoadjuvant therapy (TNT) as planned. Two patients are still in the observation period after completion of TNT.
- 5-fluorouracil / Generic mfg.
NEOADJUVANT CHEMOTHERAPY VERSUS UPFRONT SURGERY IN RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA: A NATIONAL CANCER DATABASE INTENTION-TO-TREAT ANALYSIS (Room 207A) - Apr 21, 2024 - Abstract #SSAT2024SSAT_297;
The recent NORPACT-1 trial compared neoadjuvant FOLFIRINOX (4 cycles + surgery + 8 cycles) versus adjuvant FOLFIRINOX (surgery + 12 cycles) and reported worse median survival of 25.1 months in the NAC group versus 38.5 months with upfront surgery...In the NAC group, 721 (53.9%) underwent resection following NAC and 280 (20.9%) received AC. Bivariate analysis by intention-to-treat are shown in
- 5-fluorouracil / Generic mfg.
SBRT AFTER NEOADJUVANT CHEMOTHERAPY (NAC) FOR LOCALLY ADVANCED PANCREATIC CANCER (LAPC): PRELIMINARY INSTITUTIONAL RESULTS (Room 207A) - Apr 21, 2024 - Abstract #SSAT2024SSAT_293;
The potential additional role of SBRT remains controversial.Materials and MethodsIn our tertiary referral center, patients with LAPC undergo a complete course of NAC (mostly FOLFIRINOX), cross-sectional imaging reevaluation in 2 weeks and exploration for possible resection when the tumor looks resectable, en-block with the involved major vascular structure(s)...Local control was achieved in 9 (69%). Seven patients are alive for a median of 15 months and 6 patients died at a median of 15 months.ConclusionsOur initial experience shows that SBRT following NAC for LAPC is safe, is associated with a high rate of local control and may render resectable about one third of patients considered unresectable after NAC alone.
- 5-fluorouracil / Generic mfg.
CAN TUMOR RESPONSE TO INDUCTION CHEMOTHERAPY PREDICT TME-FREE SURVIVAL AFTER TOTAL NEOADJUVANT THERAPY FOR LOCALLY ADVANCED RECTAL CANCER? (Room 207A) - Apr 21, 2024 - Abstract #SSAT2024SSAT_5;
Our data indicate that when an organ preservation strategy is pursued, the tumor response to induction chemotherapy predicts the probability of TME-free survival early in the treatment course. This benefit of induction chemotherapy should be considered when the chemotherapy sequence or treatment escalation and de-escalation, based on tumor response, is investigated in future research designed to maximize organ preservation.
- Interactions between ?? T-Cell subclass and patient derived pancreas cancer tumor organoid models indicate potential for cell-mediated intervention in PDAC (Exhibit Hall F1; Poster Board Number: B981) - Apr 20, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_2629;
??T efficiently infiltrate PCOs. Using PCOs ex vivo, we demonstrate that ??T retain cytotoxicity against PDAC, with ability to induce apoptosis exceeding that of FOLFIRINOX chemotherapy.
- 5-fluorouracil / Generic mfg.
Helminth-derived Molecules improve 5-Fluorouracil Treatment on experimental colon tumorigenesis (Exhibit Hall F1; Poster Board Number: B976) - Apr 20, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_2430;
In vitro assays with human colon cancer cell lines showed that TcES+5FU significantly reduced cell proliferation and migration by modulating the P53 and P21 signaling pathways. Our findings demonstrate that helminth-derived excreted/secreted products may potentiate the effect of 5FU on established colon tumors.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study. (Pubmed Central) - Apr 19, 2024
The FOLFOXIRI plus cetuximab regimen displayed tolerable toxicity and promising anti-tumor activity in terms of the rate of NED achieved and response rate in patients with initially unresectable left-sided RAS/BRAF wild-type CLM. This regimen merits further investigation.
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Apr 19, 2024
P2, N=78, Active, not recruiting, Sponsor: Patrick Boland
This regimen merits further investigation. Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Mar 2024
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial primary completion date, Metastases: NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 19, 2024
P2, N=200, Recruiting, Sponsor: Seoul National University Hospital
Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Mar 2024 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024